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ABSTRACT 
BACKGROUND:  Forty-eight percent of somatic symptoms encountered in the 
primary care setting are medically unexplained. Such symptoms have been associated 
with negative impact on quality of life and with functional impairment. 
oEJr-'CTJVE: The aim of this study was to assess the potential utility and 
tolerability of paroxetine for the treatment of undifferentiated somatoform disor- 
der (USD), using the 15-item Patient Health Questionnaire (PHQ-15) to assess the 
severity of somatic symptoms. 
METHODS:  A prospective, open-label, 8-week pilot study ofparoxetine was con- 
ducted in outpatients with USD. Data were collected at baseline and at weeks 1, 2, 4, 
and 8. The primary measure was the mean change in PHQ-15 total score from base- 
line to the end of treatment. Secondary effectiveness measures included mean changes 
in total scores on the Beck Depression Inventory (BDI) and the 12-item General 
Health Questionnaire from baseline to end of treatment. A physical examination, 
electrocardiography, complete blood count, blood chemistry, urinalysis, and preg- 
nancy test (for women of childbearing potential) were performed at baseline and the 
end of treatment. Vital signs were measured uring each visit. Adverse events (AEs) 
were recorded uring the study and included those determined using the Systematic 
Assessment for Treatment Emergent Events-General Inquiry. 
RESULTS:  Forty-three Korean patients were screened for the study. Twenty-two pa- 
tients (13 women, 9 men; mean [SD] age, 37.4 [12.4] years) were enrolled and 20 
completed the study; 2 patients were lost to follow-up. The mean total score on the 
PHQ-15 from baseline to the end of treatment was significantly decreased (17.2 vs 
4.3; P = 0.001), as was the mean total BDI score (12.8 vs. 6.3; P < 0.001). Overall, 
paroxetine was well-tolerated. Nausea and dry mouth were the most commonly 
reported treatment-emergent AEs (both, 5 [22.7%]); no serious AEs were reported. 
No abnormal laboratory results were observed. 
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CONCLUSION:  This open-label pilot study found that paroxetine had potential 
utility in the treatment of USD and was generally well-tolerated. These results sug- 
gest that adequately-powered, double-blind, placebo-controlled trials are warranted 
to more fully assess the efficacy and safety of paroxetine in the treatment of USD. 
(Curr Ther Res Clin Exp. 2008;69:221-231) © 2008 Excerpta Medica Inc. 
KEY WORDS:  undifferentiated somatoform disorder, paroxetine, Patient Health 
Questionnaire, pilot study. 
INTRODUCTION 
It has been reported that 48% of the somatic symptoms encountered in the primary 
care setting are medically unexplained, and ->25% of such symptoms persist beyond 
1 year in duration. 1In addition, unexplained somatic symptoms have been associated 
with negative impact on quality of life and with functional impairment. 2,3 
The neurobiologic etiology of unexplained somatic symptoms remains poorly 
understood, although dysfunctions in serotonergic and noradrenergic pathways have 
been implicated. 4 Pharmacologic treatment paradigms have yet to be developed for 
unexplained somatic symptoms; however, multiple meta-analyses 5-8have suggested a 
role for contemporary antidepressants, including tricyclic antidepressants and selec- 
tive serotonin reuptake inhibitors (SSRIs) in the treatment of unexplained somatic 
symptoms. One review 5 found that, out of 94 studies covering 6595 patients, the 
absolute difference in improvement between antidepressant and placebo groups was 
32% for certain somatic symptoms, and this has been replicated in subsequent s ud- 
ies. 6-8 Antidepressants may have a role in the treatment of somatic syndromes, and 
this role deserves to be clarified. 
To date few clinical trials have investigated the effectiveness and tolerability of 
paroxetine for patients with undifferentiated somatoform disorder (USD); particularly 
lacking are studies using objectively validated scales measuring somatic omplaints. 
The present study was conducted to assess the effect and tolerability of paroxetine* 
for the treatment of USD using the 15-item Patient Health Questionnaire (PHQ-15), 9
which was specifically designed to assess the severity of somatic symptoms. This was 
intended as a preliminary study to justify a sufficiently powered, randomized, ouble- 
blind, placebo-controlled clinical trial. 
PAT IENTS AND METHODS 
DESIGN 
This was a prospective, open-label, 8-week study in patients with USD. All clinical 
outcomes at the end of the study were compared to those at baseline in the same 
patients. This study was conducted at an outpatient clinic in a university-based train- 
ing hospital (Korea University Ansan Hospital, Ansan, South Korea). The study was 
reviewed and approved by the institutional review board. All participants provided 
written informed consent prior to entering the study. 
*Trademark: Paxil ® (GlaxoSmithKline, London, United Kingdom). 
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PAT IENTS 
All patients were recruited from advertisements in the university and local newspapers. 
Patient eligibility was determined by 2 board-certified psychiatrists (C.H. and B.H.L.) in 
accordance with protocol-specific inclusion and exclusion criteria via face-to-face interview. 
No monetary compensation was provided to patients for their participation. 
Men and women aged >18 years who met the criteria for a diagnosis of USD based on 
the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition t° (DSM-IV), who 
stated they had somatic symptoms almost every day for at least the prior 6 months and 
who were not currently receiving any prescription medications to control their somatic 
complaint (over-the-counter [OTC] medications [eg, acetaminophen <2 g/d and ibuprofen 
<1.2 g/d] were allowed) were eligible for the study. In addition, women of child-bearing 
potential were required to use approved methods of contraception. 
Exclusion criteria included previous or current psychotic disorders (eg, schizophrenia, 
schizoaffective disorder), bipolar disorder, or current Axis I disorder that might account 
for or contribute to somatic symptoms (eg, major depressive disorder, anxiety disorders, 
factitious disorder, malingering, or other somatoform disorders [eg, somatization disor- 
der]). Individuals were also excluded if they experienced substance abuse or dependence 
in the previous 12 months, had a history of hypersensitivity o paroxetine, or were cur- 
rently being treated with any psychotropic medication. Individuals who had partici- 
pated in any clinical trial in the previous 30 days or were involved in health-related legal 
proceedings (including workers' compensation or disability claims) were ineligible. 
Women who were breastfeeding or pregnant were also excluded. 
PSYCHIATRIC  D IAGNOSIS  
Axis I diagnosis was assessed by consensus between 2 board-certified psychiatrists 
(C.H. and B.H.L.) according to DSM-IV criteria m at screening visits. 
MEDICAT ION 
Paroxetine immediate-release (IR), (tablet) was administered using a flexible titra- 
tion strategy based on clinical response and patients' tolerability. The starting dosage 
was 10 mg/d and the maximum dosage was 40 mg/d. No other psychotropic medica- 
tions were permitted uring the study, except hypnotics for insomnia and benzodiaze- 
pines for anxiety on an intermittent and temporary basis. 
Prescription analgesics, muscle relaxants, and steroids were not allowed during the 
study. Concomitant as-needed OTC analgesics, including acetaminophen <2 g/d and 
ibuprofen <1.2 g/d, were permitted uring the study. 
ASSESSMENT 
The study treatment period was 8 weeks, which consisted of visits at baseline and 
weeks 1, 2, 4, and 8. Assessments for effect and tolerability were done at each visit. 
PRIMARY END POINT 
The primary measure chosen a priori was the mean change in PHQ-15 total score ll 
from baseline to the end of treatment. The questionnaire assesses 15 somatic symp- 
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toms or symptom clusters that account for >90% of all physical complaints (exclud- 
ing upper respiratory tract symptoms) reported by outpatients. Each item is rated on 
a scale from 0 to 2. Scoring is simply the sum of the numbers circled and scores can 
range from 0 to 30. 
SECONDARY END POINT 
Secondary measures were the mean changes in total scores on the Beck Depression 
Inventory (BDI) 12 and the 12-item General Health Questionnaire (GHQ-12) 13 from 
baseline to the end of treatment. The BDI contains 21 questions about emotional, 
cognitive, motivational, physiological, and other symptoms. Each item consists of 
4 statements describing increasing intensities of symptoms of depression. Items are 
rated on a scale from 0 to 3. The GHQ-12 consists of 12 items, each assessing the severi- 
ty of a mental problem over the past few weeks using a 4-point scale (from 0-3). 
TOLERABIL ITY  MEASURES 
A physical examination, electrocardiography, complete blood count, blood chemis- 
try, urinalysis, and pregnancy test (for women of childbearing potential) were per- 
formed at baseline and the end of treatment. Vital signs were measured uring each 
visit. Adverse events (AEs) were recorded during the study and included those 
determined using the Systematic Assessment for Treatment Emergent Events-General 
Inquiry. 14 Treatment-emergent AEs were defined as any AEs reported after patients were 
administered study medication. 
STAT IST ICAL  ANALYS IS  
All patients who received _>1 dose of study medication and had _>1 post baseline 
visit assessment were included in the intent-to-treat (ITT) population. The last avail- 
able post baseline measurement was assigned as an end point analysis (last observation 
carried forward [LOCF]). ITT with the LOCF approach was conducted for the analysis 
of outcomes. The primary and secondary end points relative to continuous variables 
were compared using paired t tests. Categoric variables were analyzed using descrip- 
tive statistics when appropriate. 
All statistical significance was 2-tailed and set at P < 0.05. Statistical analysis was 
determined using STATA/SE version 10.0 (StataCorp, College Station, Texas). 
RESULTS 
PAT IENTS 
Forty-three patients were screened for the study. Reasons for exclusion were as fol- 
lows: unwillingness to take study medication for >4 weeks (n = 9), comorbid psychi- 
atric disorders (eg, alcohol dependence and major depressive disorder) (n = 6), and 
withdrawal of consent (n = 6). Twenty-two Korean patients (13 women, 9 men; mean 
[SD] age, 37.4 [12.4] years) were included in the study (Table I). Patients reported 
having had chronic somatic symptoms for a mean (SD) duration of 26.0 (14.8) months 
and 2.1 (1.5) prior clinic visits to any psychiatric or medical department for such 
complaints. 
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Table I. Baseline demographic and clinical characteristics of the study patients with 
undifferentiated somatoform disorder (N = 22). 
Characteristic Value 
Age, mean (SD), y 37.4 (12.4) 
Sex, no. (%) 
Female 13 (59.1) 
Male 9 (40.9) 
Income status* 
High 1 (4.5) 
Middle 18 (81.8) 
Low 3 (13.6) 
Marital statust 
Married 14 (63.6) 
Single 5 (22.7) 
Divorced 1 (4.5) 
Education, no. (%), y 
<12 15 (68.2) 
>12 7 (31.8) 
Alcohol use, no. (%)t 
Never 7 (31.8) 
Once per week 14 (63.6) 
_>2 per week 1 (4.5) 
Smoking history, no. (%) 
No 19 (86.4) 
Yes 3 (13.6) 
Admission history, no. (%)§ 
No 19 (86.4) 
Yes 3 (13.6) 
Duration of somatic symptoms, mean (SD), mo 26.0 (14.8) 
Prior clinic visits, mean (SD), no.IP 2.1 (1.5) 
Somatic symptoms at baseline, mean (SD), no. 3.2 (2.0) 
Baseline PHQ-15 score, mean (SD) 17.2 (5.4) 
Baseline BDI score, mean (SD) 12.8 (10.5) 
Baseline GHQ-12 score, mean (SD) 16.2 (8.0) 
PHQ-15 = Patient Health Questionnaire; BDI = Beck Depression Inventory; GHQ-12 = General Health 
Questionnaire. 
*Monthly income based on 2007 analysis by Kookmin Bank, Seoul, South Korea (in approximate US$): 
high = _>$5000; middle = _>52000 to <$5000; low = <$2000. 
t Data missing for 2 patients. 
~' No patient met alcohol abuse or dependence criteria based on the Diagnostic and Statistical Manual 
of Mental Disorders--Fourth Edition. 1° 
§ Admisson for the evaluation and treatment of somatic symptoms in any department. 
IP Visits to any psychiatric or medical departments. 
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Twenty of the 22 enrolled patients (90.9%) completed the study; 2 patients were 
lost to follow-up (second and final visits, respectively). No patient discontinued due 
to AEs. All patients returned for _>1 post baseline follow-up visit, yielding an LOCF 
ITT population of 22. 
MEDICAT ION 
The mean (SD) dosage of paroxetine was 19.5 (11.5) mg/d (range, 10-40 mg/d) 
during the study. Twelve patients (54.5%) were administered lorazepam or alprazolam 
concomitantly asneeded for temporary control of mild anxiety, as deemed clinically 
appropriate by the clinical experience of the study physicians and the status of the 
patients. 
PRIMARY END POINT 
The mean total score on the PHQ-15 decreased significantly from baseline to the 
end of treatment (17.2 vs 4.3; P = 0.001). The mean reduction in PHQ- 15 total score 
from baseline was 11.0%, 19.8%, 43.0%, and 75.0%, at weeks 1, 2, 4, and 8, respec- 
tively (Figure). No patient had an increase in PHQ-15 total score at the end of treat- 
ment compared with baseline. 
SECONDARY END POINTS 
The mean total score on the BDI from baseline to the end of treatment decreased 
significantly by 50.8% (P < 0.001), while the mean reduction in the score on the 
GHQ-12 (13.0%) was not significant. 
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Figure. Change in mean Patient Health Questionnaire (PHQ-15) score from baseline 
to the end of treatment (week 8) in patients with undifferentiated somatoform 
disorder administered paroxetine 10 to 40 mg/d. *P < 0.001. 
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TOLERABILITY 
All reported AEs were considered treatment-emergent AEs. The most common 
AEs reported uring the 8-week treatment period were nausea nd dry mouth (both, 
5 [22.7%]) (Table II). No serious AEs occurred, and no patient withdrew from the 
study due to AEs. There were no clinically significant changes in laboratory or vital 
sign parameters during the study. 
DISCUSSION 
This is the first published study to assess the effect of paroxetine over 8 weeks in 
patients with USD. Paroxetine was associated with significantly reduced PHQ-15 
total score from baseline to the end of treatment. The magnitude of improvement in 
PHQ-15 total score was 75.0%, with a decrease of 12.9 points from baseline to the end 
of treatment. Although conclusions are limited by the absence of a placebo arm in the 
present study, it should be noted that the magnitude of improvement on the PHQ-15 
exceeded the typical placebo response rate (~30.0%) observed in clinical trials. 15 
Few studies have investigated the effectiveness ofSSRIs for USD using change in 
PHQ-15 total score as a primary end point. A 12-week, randomized, ouble-blind, 
placebo-controlled trial 15 in 112 patients with multisomatoform disorder with comor- 
bid anxiety or depression investigated the effect of venlafaxine extended-release (ER) 
(75-225 mg/d) on PHQ-15 score. Venlafaxine ER treatment yielded significantly 
better scores compared with placebo on the PHQ-15 pain subscale (P = 0.03); how- 
ever, improvement in PHQ-15 total score was not significant compared with placebo. 
These data suggest that venlafaxine ER reduced the pain associated with multisomato- 
form disorder but did not improve the whole symptom domain. 
In a series of studies, 16-19 paroxetine was reported to be effective for somatic symp- 
toms associated with major depressive disorders, as determined by improvements on
somatic and anxious ymptom items of depression rating scales. Additionally, paroxe- 
tine was found to be effective for various somatic syndromes, including noncardiac 
chest pain, 2° fibromyalgia, 21 irritable bowel syndrome, 22and rheumatoid arthritis. 23 
Table II. Treatment-emergent adverse events (AEs) reported In pa- 
tients with undifferentiated somatoform disorder treated with 
paroxetine* 3.0 to 40 mg/d (N = 22). 
AE No. (%) 
Nausea 5 (22.7) 
Dry mouth 5 (22.7) 
Somnolence 4 (18.2) 
Sweating 3 (13.6) 
Dizziness 3 (13.6) 
Yawning 2 (9.1) 
Headache 1 (4.5) 
*Trademark: Paxil ® (GlaxoSmithKline, London, United Kingdom). 
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A large literature review 24 of paroxetine use in physical illness with and without 
comorbid epression concluded that paroxetine may be particularly effective for treat- 
ing somatic symptoms. 
We found a significant reduction in total BDI scores from baseline to the end of 
treatment. The reduction in BDI scores might have been due to the effects of paroxe- 
tine on subsyndromal depressive symptoms. We excluded patients with current de- 
pressive and anxiety disorders from study participation to reduce the confounding 
factors of antidepressant/anxiolytic effects. Therefore, we posited that the improve- 
ment observed in somatic symptoms in the present study was not due solely to 
improvement in depressive or anxiety disorders. In accordance with this notion, there 
is copious evidence that antidepressants have a direct analgesic effect on somatic 
symptoms in patients with a variety of somatic syndromes. 5'25-27 Caution in interpret- 
ing the results of our trial is advised until more evidence-based clinical data are 
available. 
Nevertheless, our study may at least contribute to psychopharmacologic treatment 
for patients with USD by providing a tolerability profile of paroxetine, although the 
open-label study design does not provide definite information about the efficacy of a 
certain medication for a specific disease due to the lack of a placebo group. Our study 
suggested that subsequent clinical trials for the treatment of USD are needed, because 
we observed some utility of paroxetine in treating USD. Further research into the 
pathophysiology of somatic syndromes and antidepressant mechanisms of action may 
clarify the interface between somatic syndromes and depressive/anxiety disorders with 
regard to their treatment responses. Finally, this study was the first trial ofparoxetine 
for USD that suggested a preliminary possibility for control of USD. Additional clini- 
cal trials should expand our understanding of the utility of paroxetine and other 
antidepressants forsomatic syndromes. 
The mean dose of paroxetine used in this study (19.5 mg/d) was somewhat lower 
than the dose ranges approved in the treatment of major depressive disorder and anxiety 
disorders by the US Food and Drug Administration. 28Research as supported using a 
low dose (-20 mg/d) of paroxetine in patients with somatic disorder. 24 However, 
a fixed-dose trial will be necessary to confirm our dose finding. 
Common AEs seen in the present study were similar to those seen in randomized 
clinical trials of paroxetine IR. 19,29,3° Because no serious AEs were reported and no 
patients discontinued the study due to AEs, we concluded that paroxetine was well- 
tolerated in this patient population. 
One of the chief limitations of this study was its open-label design; the lack of a 
placebo group makes conclusions about the efficacy of paroxetine for USD specula- 
tive. It is possible that the observed reductions in PHQ-15 scores reflect natural 
improvement in the course of somatic symptoms as opposed to a specific treatment 
effect of paroxetine. Nevertheless, this study was the first trial of paroxetine for 
USD; the data are encouraging and suggest hat further research into the potential 
effectiveness of paroxetine and other SSRIs for somatic syndromes is warranted. 
Additionally, our study found that paroxetine had a favorable ffect in this patient 
population. 
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A challenge to further esearch in patients with USD is the need for a large sample 
size to provide statistical power to detect a significant difference between treatment 
groups. Power analysis based on a placebo-controlled clinical trial found that > 100 pa- 
tients would be needed in each group (treatment and placebo) to provide 90% power 
to detect an effect size of 0.66. 31 In the present study, the sample size of 22 provided 
80% power to detect an observed ifference in PHQ-15 score of 12.9 points from 
baseline to end point, corresponding to an effect size of 0.63. Therefore, large-scale, 
placebo-controlled studies are needed to determine whether our effect size of 0.63 
should be translated into clinical significance. 
The PHQ-15 is prone to subjective rating bias because it is entirely self- 
administered. However, the self-report feature of the PHQ-15 makes it efficient o 
use in primary care settings. The PHQ-15 has been extensively used as an outcome 
measure of somatic symptom severity and has been validated in > 6000 patients 11'25; 
however, the correlation between clinical improvement and changes in the PHQ-15 
has not been clearly established. An additional source of potential bias in the cur- 
rent study was the lack of a structured interview to establish the absence of exclu- 
sionary comorbid psychiatric disorders. We strictly assessed patients based on 
DSM-IV criteria, but we could not completely exclude the impact of hidden comor- 
bid psychiatric symptoms on the positive effect of paroxetine on the outcome mea- 
sures. An exclusion of comorbid psychiatric disorders was another limitation on the 
ability to generalize our results and on the subgroup analysis based on mood and 
anxiety symptoms, given the frequent mood and anxiety disorder comorbidity in 
somatic syndromes. 
An additional limitation of the study was its short duration. Because somatic syn- 
dromes tend to be chronic and recurrent, 1 treatments must be associated with effec- 
tiveness in long-term studies to be applicable in real clinical practice settings. 
CONCLUSION 
This open-label pilot study found that paroxetine IR was generally well-tolerated and 
was associated with a significant decrease in the severity of somatic symptoms 
measured by PHQ-15 from baseline to the end of treatment. Large, double-blind, 
placebo-controlled, long-term studies are needed to assess the efficacy and safety of 
paroxetine IR in the treatment of patients with USD. 
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